Document is current
Any future updates will be listed below
-
Authors
Izumi, Akihiko
Tachibana, Takayoshi
Nukui, Jun
Miyazaki, Takuya
Hirose, Natsuki
Ohashi, Takuma
Tanaka, Marika
Katsuki, Kengo
Suzuki, Taisei
Nakajima, Yuki
Matsumoto, Kenji
Fujisawa, Shin
Tanaka, Masatsugu
Nakajima, Hideaki
- License Information
-
More Information
Article History
Received: 6 January 2025
Accepted: 13 June 2025
First Online: 3 July 2025
Declarations
:
: The study protocol was approved by the Institutional Review Board (IRB) of the participating institutions (Kanagawa Cancer Center 2022-eki-22, Yokohama City University Medical Center F220700057, Yokohama City University Hospital F220700056) and complied with the Declaration of Helsinki. The requirement for informed consent was waived by the IRB, considering that no intervention was involved due to the retrospective nature of this study.
: TT reports honoraria from Pfizer, Otsuka, MSD, Chugai, AbbVie, Astellas, Novartis, Nippon Shinyaku, Asahi Kasei Pharma, Daiichi Sankyo, and Amgen, outside the submitted work. SF reports honoraria from Novartis, Pfizer, Otuska Pharmaceutical, Nipppon Shinyaku, Chugai Pharmaceutical, Takeda, Janssen, AstraZeneca, AbbVie Inc, Meiji Seika Pharma, AsahiKasei, CSL Behring K.K, Asahi Kasei Pharma, Daiichi Sankyo, Kyowa Hakko Kirin, Kissei, PharmaEssentia Japan, Genmab, Argenx Japan, and Amgen, and research funding from Amgen, Otuska Pharmaceutical, Kyowa Hakko Kirin, Chugai Pharmaceutical, and AsahiKasei, outside the submitted work.
